Methixene Hydrochloride
FDA-approved product (tablet, oral), marketed as Trest.
- Registered studies
- 0
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Parkinson disease
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Tertiary amines
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA37.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli34.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae17.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis66.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Methixene Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mitapivat SulfateExisting use: Anemia, Familial hemolytic anemia, Genetic disorder60.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Trilaciclib DihydrochlorideExisting use: Small cell lung carcinoma60.4% AI-predicted activityagainst M. tuberculosis2 registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more60.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- FlumazenilExisting use: Antidotes60.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Nintedanib EsylateExisting use: Idiopathic pulmonary fibrosis, Interstitial pneumonitis, Non-small cell lung carcinoma and 1 more60.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- RegorafenibExisting use: Cancer, Colorectal adenocarcinoma, Colorectal cancer and 3 more60.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Trypan BlueExisting use: Other surgical aids60.2% AI-predicted activityagainst M. tuberculosis23 registered studies
- Flurazepam HydrochlorideExisting use: Insomnia60.1% AI-predicted activityagainst M. tuberculosis2 registered studies
- Goserelin AcetateExisting use: Breast cancer, Breast carcinoma, Carcinoma and 1 more60.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ApremilastExisting use: Behcet's syndrome, Immune system disease, Oral ulcer and 4 more60.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Cerivastatin SodiumExisting use: Cardiovascular disease60.0% AI-predicted activityagainst M. tuberculosis1 registered study
- Givinostat HydrochlorideExisting use: Duchenne muscular dystrophy60.0% AI-predicted activityagainst M. tuberculosis23 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.